REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Running, not enrolling · Phase 3

Conditions studied: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

In brief

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.

Key facts

Study ID
NCT05973773
Run by
Taiho Oncology, Inc.
People needed
285
Starts
2023-12-18
Expected to finish
2027-05-27
Last updated by the study team
2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.